Chemistry:Famitinib
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H27FN4O2 |
| Molar mass | 410.493 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers.[1][2][3][4][5][6]
References
- ↑ Chen, Li; Jiang, Yi-Zhou; Wu, Song-Yang; Wu, Jiong; Di, Gen-Hong; Liu, Guang-Yu; Yu, Ke-Da; Fan, Lei et al. (1 July 2022). "Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial". Clinical Cancer Research 28 (13): 2807–2817. doi:10.1158/1078-0432.CCR-21-4313. PMID 35247906.
- ↑ Xie, Cen; Zhou, Jialan; Guo, Zitao; Diao, Xingxing; Gao, Zhiwei; Zhong, Dafang; Jiang, Haoyuan; Zhang, Lijia et al. (April 2013). "Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients". British Journal of Pharmacology 168 (7): 1687–1706. doi:10.1111/bph.12047. PMID 23126373.
- ↑ Qu, Yuan-Yuan; Zhang, Hai-Liang; Guo, Hongqian; Luo, Hong; Zou, Qing; Xing, Nianzeng; Xia, Shujie; Sun, Zhongquan et al. (1 November 2021). "Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study". Clinical Cancer Research 27 (21): 5838–5846. doi:10.1158/1078-0432.CCR-21-1698. PMID 34400414.
- ↑ Zhou, Aiping; Zhang, Wen; Chang, Chunxiao; Chen, Xiaoyan; Zhong, Dafang; Qin, Qiong; Lou, Donghua; Jiang, Haoyuan et al. (November 2013). "Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib". Cancer Chemotherapy and Pharmacology 72 (5): 1043–1053. doi:10.1007/s00280-013-2282-y. PMID 24043137.
- ↑ Xia, Lingfang; Zhou, Qi; Gao, Yunong; Hu, Wenjing; Lou, Ge; Sun, Hong; Zhu, Jianqing; Shu, Jin et al. (2022-12-08). "A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma". Nature Communications (Springer Science and Business Media LLC) 13 (1): 7581. doi:10.1038/s41467-022-35133-4. ISSN 2041-1723. PMID 36481736.
- ↑ Xu, Rui-Hua; Shen, Lin; Wang, Ke-Ming; Wu, Gang; Shi, Chun-Mei; Ding, Ke-Feng; Lin, Li-Zhu; Wang, Jin-Wan et al. (2017). "Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial". Chinese Journal of Cancer (Springer Science and Business Media LLC) 36 (1): 97. doi:10.1186/s40880-017-0263-y. ISSN 1944-446X. PMID 29273089.
 |  |
